Cue Biopharma reçoit un paiement de jalonnement de 7,5 millions de dollars de Boehringer Ingelheim | Benzinga France
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases - Slideshow (NASDAQ:CUE) 2026-04-09
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript